MDS 2021 | Immunotherapy in MDS
David Sallman, MD, of the Moffitt Cancer Center, Tampa, FL, gives his views on where the future of myelodysplastic syndrome (MDS) research is headed, and explains the importance of expanding the immune armory. Preclinical studies showed hypomethylating agents upregulate immune checkpoints, a potential mechanism of resistance and thus supporting the use of immune checkpoint therapies. Further studies outlines single agents as well as combination treatments targeting the immune system; CD47-targeting agents like the monoclonal antibody magrolimab as well as sabatolimab, a T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3)-targeting immunotherapeutic agent, have shown great promise in clinical trials. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.
